Abstract: The present invention provides a substantially clear gel designed to reduce itching discomfort when applied to the vulvar tissue. The gel includes at least one anesthetic, protectant, emulsifier, and pH modifier, such as a base. The gel has a pH adapted to vulvar use and may be applied to the vulvar tissues.

Abstract: The present invention relates to methods and pharmaceutical compositions for treating obesity or obesity-related disorders in a subject suffering from or predisposed to developing obesity or an obesity-related disorder, or for inhibiting the infectivity of HIV, by administering oleuropein, an analogue or derivative thereof, or the major metabolites of oleuropein including oleuropein aglycone, hydroxytyrosol, and elenolic acid or their analogues, or derivatives thereof, an iridoid glycoside, or a secoiridoid glycoside or analogues or derivatives thereof, or any combination of the foregoing including olive leave extract. The invention also relates to methods for screening/diagnosing a subject having, or predisposed to having obesity or a related disorder by measuring the expression profiles of an adipogenic gene selected from PPAR?2, LPL and ?P2 gene and gene product, or other adipogenic, lipogenic, or lipolytic genes and gene products in an individual.

Abstract: The present invention provides a skin cosmetic having an excellent whitening effect to inhibit skin tanning by ultraviolet rays and having high safety. The skin cosmetic product includes a melanogenesis inhibitor comprising as an active ingredient an acylated biphenol compound represented by the following general formula (1): wherein R1 and R2 are each a hydrogen atom or an acyl group having 2 to 10 carbon atoms, provided that both R1 and R2 are not hydrogen atoms; and R3 and R4 are each a hydrogen atom or a linear or branched saturated hydrocarbon group having 1 to 8 carbon atoms.

Abstract: The field of the invention relates to the use of carbohydrate binding compounds as a medicine, their use to treat or prevent viral infections, their use to manufacture a medicine to treat or prevent viral infections and their use in a vaccination strategy. The present invention relates to the use of said compounds to manufacture a medicine to treat or prevent viral infections of subjects, more in particular infections with viruses having glycosilated envelop proteins such as Retroviridae (i.e. Lentivirinae), like HIV (human immunodeficiency virus), Flaviviridae, like HCV (hepatitis C virus), Hepadnaviridae, like HBV (hepatitis B virus), Coronaviridae, like SARS corona virus, and Orthomyxoviridae, like influenza A, B or C.

Abstract: A liquid cleansing composition comprising a cleansing surfactant, an adsorbed skin-care agent, adsorptive polymeric particles having an adsorption capacity of at least 2 g of skin care agent per gm of dry polymeric particles, a polymeric thickening agent having a molecular weight in the range of 500,000-10,000,000 Dalton, a water-soluble polymer having a molecular weight in the range of 200-50,000 Dalton, and a hydrophilic liquid, the said cleansing composition having the following features i) the low molecular weight, water-soluble polymer component functions as a foam-boosting and thixotropy-boosting agent; ii) the ratio of the Brookfield viscosity at 1 rpm of spindle speed to the Brookfield viscosity at 100 rpm of spindle speed is at least 10; and iii) the foam-volume is at least 20% higher with the water-soluble, polymeric, foam-boosting component than without it.

Abstract: A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, e.g., insulin dependent diabetes mellitus (type 1 diabetes) or noninsulin-dependent diabetes mellitus (type 2 diabetes), complications of diabetes, and obesity.

Abstract: The present invention includes compositions and methods treat a patient suffering from one or more symptoms of cardiac hypertrophy, hypertension and/or ischemia by administering a pharmaceutically effective amount of a pharmaceutical composition having an anti-epileptic drug and an antibiotic to the patient, for example, the anti-epileptic drug may be carbamazepine and the antibiotic may be doxycycline.

Abstract: Disclosed are anti-viral compositions containing at least one zinc compound and at least one phenolic antioxidant (and optionally other ingredients), and a pharmaceutical carrier. Also disclosed are methods of treating lesionous symptoms of a viral infection involving applying an effective amount of the anti-viral composition to the lesions.

Abstract: The present invention provides novel honokiol derivatives, as well as pharmaceutical compositions containing the honokiol derivatives. These compounds and pharmaceutical compositions can be used in the prevention and/or treatment of cancer. In particular, honokiol derivatives, pharmaceutical compositions comprising the derivatives, and methods for their use in the treatment of myeloma are provided.

Abstract: The present invention relates to compositions for the treatment of pilosebaceous gland inflammations, especially of the hair follicle and its appendages, in particular of Acne Vulgaris and Folliculitis, comprising as active ingredient AIF or chemical compounds which finally release AIF, or combinations of aluminum and fluoride salts which finally release AIF. AIF in accordance with the present invention relates to Aluminum fluoride (Aluminum Trifluoride; Aluminum Fluoride), CAS No 7784-18-1, EINECS No. 232-051-1, having an empirical formula of AIF3. Said compositions have, inter alia, pharmaceutical, cosmetic or quasi-cosmetic properties. The present invention also relates to the use of said compositions in said treatment, and to methods for the treatment of pilosebaceous gland inflammations with said compositions.

Abstract: Antimicrobial compositions having a rapid antiviral and antibacterial effectiveness, and a persistent antiviral effectiveness, are disclosed. The antimicrobial compositions contain a phenolic antimicrobial agent, a surfactant, a hydrotrope, a hydric solvent, and an organic acid, wherein the phenolic antimicrobial agent is present in a continuous aqueous phase in an amount of at least 25% of saturation concentration and the composition has a pH of about 5 or less.

Abstract: The present invention relates to systems and methods using colorimetric indicators of oxidation in consumer products. In particular, betalains are used as oxidation indicators in food, pharmaceutical, and other products.

Abstract: The present invention relates to a compound of formula I, or a pharmaceutically acceptable salt thereof. Formula (I), wherein R1 and R2 are each independently H or alkyl; Y is an alkyl group. CONR3R4, COOR5SO2NR16R17, NHSO2R18 or CN; X is an aryl or heteroaryl group, each of which may be optionally substituted with one or more substituents selected from (CH2)mZ where Z is halogen, OH, CN, alkyl, alkoxy, NO2, CF3, CONR6R7, CN, NR8R9, COOR10 or NHCOR11 and m is 0 to 3; R3 to R11 are each independently H, alkyl or aryl, wherein said alkyl and aryl groups are optionally substituted by one or more substituents selected from halogen, OH, CN, alkyl, alkoxy, NO2, CF3, CONR12R13, CN, NH2, COOR14, NHCOR15, and CN; R12 to R18 are each independently H or alkyl, more preferably H or Me; n is 1 to 6; wherein the compound is other than 3?,5?-dimethyl-4-(1,1-dimethylheptyl)-1,1?-biphenyl-2-ol.

Abstract: Therapeutic methods of treatment, compositions and foodstuffs are described which contain isoflavone compounds described by general formula (I), in which Z is H, R1 is H, or RACO where RA is C1-10alkyl or an amino acid, R2 is H, OH, or ORB where RB is an amino acid, or CORA where RA is as previously defined, W is H, A is H or OH, and B is selected from (a), (b), (c), or W is H, and A and B taken together form a six-membered ring selected from (d), or W, A and B taken with the groups with which they are associated comprise (e), or W and A taken together with the groups with which they are associated comprise (f) and B is (g) wherein R3 is H, CORA where RA is as previously defined, CO2RC where RC is C1-10alkyl, or CORB where RB is as previously defined, R4 is H, CORD where RD is H, OH, C1-10alkyl or an amino acid, CO2RC where RC is as previously defined, CORE where RE is H.

Abstract: The present invention relates to a process for treating, by means of eugenol or clove oil, reservoirs for storing cereals, oil-producing plants, dry fruit or dry vegetables contaminated with mycotoxins.

Abstract: A method is provided for treating a patient in need of therapy for central nervous system inflammation comprising administering to that patient a therapeutically effective amount of a cannabinoid agonist having efficacy at the CB2 receptor but having substantially no efficacy at the CB1 receptor at that amount.

Abstract: This invention relates to a stabilized honey bee pheromone and methods of stabilizing the honey bee brood pheromone, thereby enabling the production and sustained use of commercial products based on that pheromone. The stabilized pheromone can be used to manipulate the behavior and improve the performance of worker honey bees, resulting in overall increased vigor of the hive. The pheromone composition comprises two or more of ethyl linoleate, ethyl linolenate, ethyl oleate, ethyl palmitate, ethyl stearate, methyl linoleate, methyl linolenate, methyl oleate, methyl palmitate and methyl stearate and an antioxidant.

Abstract: Pharmaceutical compositions and methods of treating conditions such as angiogenic-, neoplastic-, and cancer-related conditions and skin conditions are disclosed. The methods include administering to a host in need of treatment an effective amount of at least one honokiol-type compound and/or at least one magnolol-type compound. In addition, the pharmaceutical compositions include at least one honokiol-type compound and/or at least one magnolol-type compound in combination with a pharmaceutically acceptable carrier. The honokiol-type compound and/or magnolol-type compound are present in a dosage level effective to treat conditions listed above.

Abstract: A method for controlling body fat in a human or nonhuman animal includes the step of reducing lipoxygenase activity in an animal. Lipoxygenase activity can be reduced by reducing the enzyme activity or by lowering the enzyme level. Reduced lipoxygenase activity correlates with reduced cell-associated LPL activity and with reduced cellular triacylglyceride level.

Abstract: An object of the present invention is to provide a hydroquinone-containing composition for external use in which cytotoxicity and skin irritating properties are reduced. The composition for external use of the present invention is prepared by adding a tocopherol together with hydroquinone. Among tocopherols, ?- and ?-tocopherols are particularly effective for achieving the above object. The composition can be used as a cosmetic composition, skin cleansing composition, or pharmaceutical composition.

Abstract: A composition for the treatment of skin comprises a carboxylated, acidic amino acid obtained by acidifying an acidic amino acid with a carboxylic acid. The resultant material, which is also referred to as a tricarboxylic acid or an amino fruit acid, has significant benefit for the treatment of a number of skin conditions. In addition, the composition of the present invention is very noncaustic to skin, even when employed at a pH as low as 0.5. Also disclosed herein are therapeutic methods and compositions which employ the carboxylated acidic amino acids.

Abstract: Non-toxic, naturally derived and economical compositions for treating and preventing bacterial or fungal disease in plants, especially citrus canker, wherein such compositions include various combinations of d-limonene, wax and monohydric alcohol are provided. Methods for making and using such compositions are also provided.

Abstract: This invention relates to devices, kits, and methods for eliminating termite colonies. The kits, devices, and methods employ a termiticidal bait matrix containing a) a termiticide selected such that the termiticide causes death to about 50 to about 100% of termites within about 24 to about 84 days after the termites begin to ingest the termiticide or the bait matrix comprising the termiticide, b) a cellulose containing material, and c) water. The termiticidal bait matrix can be used in a bait station installed in the ground. The kits are suitable to be used by consumers in their homes.

Abstract: The present invention provides a method of inhibiting the formation of infectious herpes virus particles, particularly infectious herpes simplex virus (HSV) particles, in a host cell. The method involves administering an effective amount of a hydroxylated tolan, particularly a polyhydroxylated tolan, to a herpes virus infected host cell. The present invention also provides a method of treating a herpes virus infection, particularly an HSV infection. The method comprises administering a topical composition comprising a therapeutically effective amount of a hydroxylated tolan to a herpes virus-infected site. The present invention also relates to a topical composition for treating a herpes virus infection selected from the group consisting of an HSV infection, a cytomegalovirus infection, and a varicella zoster virus infection. The present invention also provides a method of treating a subject infected with Neisseria gonorrhea.

Abstract: The present invention provides a method of inhibiting the formation of pseudorabies particles in a host cell. The method involves administering an effective amount of a poly-hydroxylated stilbene, particularly resveratrol, to a herpes virus infected host cell. The present invention also provides a method of reducing or inhibiting the growth of Neisseria gonorrhea and Neisseria meningiditis in vitro and in vivo. The method comprises administering a composition comprising a therapeutically effective amount of a tri-hydroxylated stilbene to a growth surface which has come into contact or could come into contact with the bacterium.

Abstract: An injectable formulation of a sedative hypnotic drug, such as the anesthetic drug propofol, that is pharmaceutically stable and demonstrates a reduced incidence of pain upon injection. The formulation of the present invention employs a sulfoalkyl ether cyclodextrin solubilizing and complexing excipient, such as CAPTISOL® cyclodextrin (sulfobutyl ether ?-cyclodextrin) to form a true aqueous solution and not a suspension. This formulation minimizes the allergic response and microbial contamination issues typically associated with propofol parenteral formulations. The present formulation may also reduce pain on injection as compared to the known emulsion type propofol formulations. The liquid formulation can be sterile filtered unlike emulsion-type formulations of sedative hypnotics. The liquid formulation can be lyophilized or otherwise dried to yield a solid formulation.

Abstract: There are provided biocompatible chemical compositions having oxygen transporting capability and comprising oxygen transporting molecules chemically bound to antioxidants, to form compositions capable of protecting a mammalian body from oxidative damage. An example of a composition according to the invention is hemoglobin covalently coupled to a 6-hydroxy chroman carboxylic acid, such as Trolox.

Abstract: Disclosed are several preferred embodiments of hydrogen peroxide which are packaged with ease of use and extended shelf-life in mind. The embodiments include foam, mist, gel, and disposable towelette forms of H2O2. Optional ingredients of topical pain relievers and skin protectants are also disclosed, as are their methods of use.

Abstract: Provided is a method of treating hypertension, which comprises administering an effective amount of a compound represented by the following formula (1) or (2): wherein, R1 and R2 are the same or different and each independently represents hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkenyl, alkoxyalkyl, aryl, alkylaryl, aralkyl, or acyl, R3 represents hydroxyl, ester bond residue, or amide bond residue, R4 represents ester bond residue or amide bond residue, or a pharmaceutically acceptable salt thereof (except ferulic acid). When the preventive or remedy for hypertension according to the present invention is administered, ferulic acid exists in the blood for a long period of time, thereby continuously suppressing a blood pressure rise. Moreover, the hypertension preventive or remedy according to the present invention has reduced in bitterness peculiar to ferulic acid, which enables patients to take it continuously.

Abstract: A method is provided for treating inflammatory respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). The method involves administration, preferably oral or pulmonary administration, of an active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, prodrugs and analogs thereof, and combinations of any of the foregoing. Pharmaceutical formulations for use in conjunction with the aforementioned method are provided as well.

Abstract: A pharmaceutical composition for prevention and treatment of cancer, cardiovascular disease and antioxidation contains resveratol. The new method of process for producing resveratol is extracted resveratol from oil residue and stems of peanuts or stems of other cheap herbs. Derivates of resveratol include procyanidins, polydatin, peceid, anthraglycoside, emodin, chrysophanol and quercetin.

Abstract: The present invention relates to the use of certain resorcinol derivatives as skin lightening agents.

Abstract: A composition and an associated method of treating cancer cells by impeding cancer cell growth with the composition are disclosed. The composition includes at least a first and a second HMG-CoA reductase inhibitor, wherein the total amount of the first and second HMG-CoA reductase inhibitors is effective in synergistically impeding cancer cell growth and wherein the cancer cell growth synergistic impedance from the total amount of the first and second HMG-CoA reductase inhibitors is greater than a theoretical additive effect from the combined first and second HMG-CoA reductase inhibitors. The present composition does not simultaneously contain both a tocotrienol and an ionone when the composition contains only a first and a second HMG-CoA reductase inhibitor. The method includes treating cancer cells with the claimed composition to impede cancer cell growth.

Abstract: Polyhydroxylated aromatic compounds, and compositions containing them, are useful for the treatment of amyloidosis, especially Alzheimer's disease, and for the treatment of diseases characterized by &agr;-synuclein fibril formation, especially Lewy body disease and Parkinson's disease.

Abstract: Triphenylmethane derivatives of the formula (I) are disclosed.

Abstract: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A&bgr; amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Abstract: The present invention provides a preparation for hair and/or scalp which is effective in growing hair and preventing hair removal and has an excellent skin-care effect on the scalp and high safety. The preparation comprises, as active ingredients, either oxidized coenzyme Q and reduced coenzyme Q or reduced coenzyme Q alone, the total content of oxidized coenzyme Q and reduced coenzyme Q being 0.0001 to 99% by weight based on the whole of the preparation.

Abstract: The present invention relates to new antioxidative and cytotoxic hydroquinone compounds 10′(Z),13′(E),15′(E)-heptadecatrienylhydroquinone (1) and 10′(Z),13′(E)-heptadecadienylhydroquinone (2) that were mainly isolated from an ethanol extract of the sap of Rhus succedanea. The structures of these compounds were determined by spectral analyses and showed potent antioxidative activity and cytotoxicity against human cancer cells. This invention also includes anti-tumor pharmaceutical composition of the hydroquinone compounds.

Abstract: The present invention comprises a method for the treatment of cancerous tumors in mammals comprising the administration of an effective amount of an immunostimulator which enhances and potentiates the mammals own immune system to selectively attack and kill the cancerous cells. The immunostimulator, preferably urushiol, is administered in a pharmaceutically acceptable carrier and can be co-administered in conjunction with other immunostimulators, radiation therapy or other cytotoxic anti-cancer agents to further enhance their effect.

Abstract: A guest host assembly comprising a host assembly formed of calixarene molecules and a guest component located within the host assembly. A crystallographic assembly of layers of the calixarene molecules and stacked along the crystallographic c axis of the assembly in a repeating configuration associated together predominantly by van der Waal forces. The guest component is transferable through the host assembly in a direction normal to the stacked layers. The calixarene molecules are configured in bilayers of adjacent layers along the c axis. The bilayers are shifted along the a or b axis so the assembly, relative to a corresponding assembly of the calixarene molecules without the inclusion of the guest component is shifted. The calixarene are calix(N)arenes in which N is an integer within the range of 4-8. The calixarene molecules are distally substituted with a substituent such as methyl, ethyl, propyl, butyl amyl or phenyl groups.

Abstract: One aspect of the invention relates to anti-viral composition containing at least one zinc compound and at least one phenolic antioxidant (and optionally other ingredients such as at least one analgesic) at least one hydrocarbyl containing compound, and water. Another aspect of the invention relates to a method of treating lesionous symptoms of a viral infection involving applying an effective amount of the zinc containing anti-viral composition to the lesions.

Abstract: A method of forming a water soluble biocidal film on a solid household, food preparation, or medical surface, which protects the solid surface against reinfection by microorganisms, includes providing a liquid biocidal composition comprised of, based on total weight of the liquid biocidal composition from 0.1 to 5.0 wt. % of a phenolic biocide; from an amount effective to impart film-forming properties to the liquid biocidal composition up to 8 wt. % of a polyvinyl pyrrolidone polymer or copolymer; and an aqueous alcoholic solvent in which the phenolic biocide and the polyvinylpyrrolidone polymer or copolymer are dissolved; treating the solid surface with the liquid biocidal composition; and evaporating the aqueous alcoholic solvent to provide a clear film, wherein a ratio of the phenolic biocide to the polyvinylpyrrolidone polymer or copolymer is selected to range from 1:0.8 to 1:3 so that a complex there between is provided which dries clear.

Abstract: A cream base for the topical application of skin care therapeutics and a process for making the cream base. In one embodiment, the therapeutic is tretinoin, hydroquinone and fluocinolone acetonide for the treatment of hyperpigmented skin conditions, such as melasma.

Abstract: This invention relates to devices, kits, and methods for eliminating termite colonies. The kits, devices, and methods employ a termiticidal bait matrix containing a) a termiticide selected such that the termiticide causes death to about 50 to about 100% of termites within about 24 to about 84 days after the termites begin to ingest the termiticide or the bait matrix comprising the termiticide, b) a cellulose containing material, and c) water. The termiticidal bait matrix can be used in a bait station installed in the ground. The kits are suitable to be used by consumers in their homes.

Abstract: A pharmaceutical composition for the administration of phloroglucinol includes phloroglucinol in combination with a buffer system capable of buffering the composition when placed in an aqueous medium to a pH between 3 and 7.

Abstract: Method for preventing or inhibiting the transmission of HIV to susceptible uninfected cells by administering to the HIV, to cells infected with HIV, and/or to the uninfected cells, an effective amount of a compound of formula (I), wherein X is O or S, prior to the HIV or the cells infected with HIV, contacting the uninfected cells.

Abstract: Compounds of formula (I), wherein R 5 is an [A]—CH 3 , —[A]—C(OH)ZZ′ or —[A]—C(O) Z″ grouping where —[A]— is an alkylene, alkenylene or alkynylene radical or a single bond, and Z, Z′ and Z″ are a hydrogen atom or an optionally substituted alkyl, alkenyl, alkynyl or aryl radical; and R 1, R 2, R 3, R 4, R 6, R 7 and R 8 are as defined in the description; the use thereof as a drug, pharmaceutical compositions containing same, a preparation method therefor, and intermediates of said method, are disclosed.

Abstract: The invention relates to the use of phenolic compounds and derivatives thereof for protection against neurodegenerative diseases, to compositions comprising these compounds, and to some novel phenolic compounds.

Abstract: A composition for the treatment of skin comprises a carboxylated, acidic amino acid obtained by acidifying an acidic amino acid with a carboxylic acid. The resultant material, which is also referred to as a tricarboxylic acid or an amino fruit acid, has significant benefit for the treatment of a number of skin conditions. In addition, the composition of the present invention is very noncaustic to skin, even when employed at a pH as low as 0.5. Also disclosed herein are therapeutic methods and compositions which employ the carboxylated acidic amino acids.

Abstract: A method for suppressing undesired viral growth in a host which comprises administering to the host an effective amount of a compound of the formula: wherein R1, R2, R3 and R4 are independently selected from the group consisting of HO—, CH3O— and CH3(C?O) O—. The method is exemplified by inhibiting Tat transactivation of a lentivirus and in suppressing Herpes simplex virus.